Chad T. Jacobsen
Experienced in Perlman Syndrome

Dr. Chad T. Jacobsen

Hematology | Oncology
1001 Blythe Blvd., Suite 3000, 
Charlotte, NC 
On Staff At
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
28 Years of Experience
Experienced in Perlman Syndrome
1001 Blythe Blvd., Suite 3000, 
Charlotte, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Chad Jacobsen is a Hematologist and an Oncologist in Charlotte, North Carolina. Dr. Jacobsen has been practicing medicine for over 28 years and is rated as an Experienced provider by MediFind in the treatment of Perlman Syndrome. His top areas of expertise are Neurofibromatosis Type 1 (NF1), Medulloblastoma, Neurofibromatosis, and Embryonal Tumor with Multilayered Rosettes. Dr. Jacobsen is currently accepting new patients.

His clinical research consists of participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
University Of Texas, 1997, 1997
Residency
Rainbow Babies and Children's Hospital, Pediatrics, 2000
Specialties
Hematology
Oncology
Licenses
Pediatrics in NC
Board Certifications
American Board Of Pediatrics, Pediatric Hematology And Oncology
Fellowships
Rainbow Babies and Children's Hospital, Pediatric Hematology/Oncology, 2003
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

Atrium Health Levine Children’s Cancer & Blood Disorders, a facility of Carolinas Medical Center
1001 Blythe Blvd., Suite 3000, Charlotte, NC 28203
Other Locations
Levine Children's Hospital
1000 Blythe Blvd., Charlotte, NC 28203

Additional Areas of Focus

Dr. Jacobsen has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)
Brain Tumor
Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

PEACH TRIAL- Precision mEdicine and Adoptive Cellular tHerapy for the Treatment of Recurrent Neuroblastoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG)
PEACH TRIAL- Precision mEdicine and Adoptive Cellular tHerapy for the Treatment of Recurrent Neuroblastoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG)
Enrollment Status: Recruiting
Publish Date: October 09, 2025
Intervention Type: Biological
Study Drug: Tumor-Specific Ex Vivo Expanded Autologous Lymphocyte Transfer (TTRNA-xALT)
Study Phase: Phase 1
A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 Erbumine as a Single Agent and in Combination in Patients With Relapsed/Refractory Neuroblastoma
A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 Erbumine as a Single Agent and in Combination in Patients With Relapsed/Refractory Neuroblastoma
Enrollment Status: Active_not_recruiting
Publish Date: July 23, 2025
Intervention Type: Drug
Study Drugs: LY3295668 Erbumine, Topotecan, Cyclophosphamide
Study Phase: Phase 1
A Phase 1, Open-Label, Dose-Escalation Study of Olaratumab as a Single Agent and in Combination With Doxorubicin, Vincristine/Irinotecan, or High-Dose Ifosfamide in Pediatric Patients With Relapsed or Refractory Solid Tumors
A Phase 1, Open-Label, Dose-Escalation Study of Olaratumab as a Single Agent and in Combination With Doxorubicin, Vincristine/Irinotecan, or High-Dose Ifosfamide in Pediatric Patients With Relapsed or Refractory Solid Tumors
Enrollment Status: Completed
Publish Date: May 20, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1b Trial to Assess the Modulation of Biological Markers in Patients With Potentially Resectable Soft Tissue Sarcoma Treated With Olaratumab Monotherapy Followed by Olaratumab Plus Doxorubicin Combination Therapy
A Phase 1b Trial to Assess the Modulation of Biological Markers in Patients With Potentially Resectable Soft Tissue Sarcoma Treated With Olaratumab Monotherapy Followed by Olaratumab Plus Doxorubicin Combination Therapy
Enrollment Status: Completed
Publish Date: August 12, 2019
Intervention Type: Drug, Radiation
Study Phase: Phase 1
View 3 Less Clinical Trials

1 Total Publications

Phase I study of tandem high-dose chemotherapy with autologous peripheral blood stem cell rescue for children with recurrent brain tumors: a Pediatric Blood and MarrowTransplant Consortium study.
Phase I study of tandem high-dose chemotherapy with autologous peripheral blood stem cell rescue for children with recurrent brain tumors: a Pediatric Blood and MarrowTransplant Consortium study.
Journal: Pediatric blood & cancer
Published: August 24, 2010
Similar Doctors
Amy Kelly
Experienced in Perlman Syndrome
Amy Kelly, NP
Nurse Practitioner | Hematology | Oncology
Experienced in Perlman Syndrome
Amy Kelly, NP
Nurse Practitioner | Hematology | Oncology

Atrium Health Levine Children’s Cancer & Blood Disorders, A Facility Of Carolinas Medical Center

1001 Blythe Blvd., Suite 3000, 
Charlotte, NC 
 (0.1 miles away)
704-381-9900
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Amy Kelly is a Hematologist and an Oncologist in Charlotte, North Carolina. Ms. Kelly is rated as an Experienced provider by MediFind in the treatment of Perlman Syndrome. Her top areas of expertise are Pediatric Low-Grade Glioma (pLGG), Marshall-Smith Syndrome, Megalencephaly-Capillary Malformation Syndrome, and Perlman Syndrome. Ms. Kelly is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Jacobsen's expertise for a condition
ConditionClose
        View All 13 Experienced Conditions
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile